210 related articles for article (PubMed ID: 20668052)
1. Protection from doxorubicin-induced cardiomyopathy using the modified anthracycline N-benzyladriamycin-14-valerate (AD 198).
Cai C; Lothstein L; Morrison RR; Hofmann PA
J Pharmacol Exp Ther; 2010 Oct; 335(1):223-30. PubMed ID: 20668052
[TBL] [Abstract][Full Text] [Related]
2. Heat shock protein 20 interacting with phosphorylated Akt reduces doxorubicin-triggered oxidative stress and cardiotoxicity.
Fan GC; Zhou X; Wang X; Song G; Qian J; Nicolaou P; Chen G; Ren X; Kranias EG
Circ Res; 2008 Nov; 103(11):1270-9. PubMed ID: 18948619
[TBL] [Abstract][Full Text] [Related]
3. N-Benzyladriamycin-14-valerate (AD 198): a non-cardiotoxic anthracycline that is cardioprotective through PKC-epsilon activation.
Hofmann PA; Israel M; Koseki Y; Laskin J; Gray J; Janik A; Sweatman TW; Lothstein L
J Pharmacol Exp Ther; 2007 Nov; 323(2):658-64. PubMed ID: 17693586
[TBL] [Abstract][Full Text] [Related]
4. How to protect doxorubicin-induced cardiomyopathy in male albino rats?
Shaker O; Sourour DA
J Cardiovasc Pharmacol; 2010 Mar; 55(3):262-8. PubMed ID: 20051877
[TBL] [Abstract][Full Text] [Related]
5. Folic acid reduces doxorubicin-induced cardiomyopathy by modulating endothelial nitric oxide synthase.
Octavia Y; Kararigas G; de Boer M; Chrifi I; Kietadisorn R; Swinnen M; Duimel H; Verheyen FK; Brandt MM; Fliegner D; Cheng C; Janssens S; Duncker DJ; Moens AL
J Cell Mol Med; 2017 Dec; 21(12):3277-3287. PubMed ID: 28608983
[TBL] [Abstract][Full Text] [Related]
6. Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect.
Koka S; Das A; Zhu SG; Durrant D; Xi L; Kukreja RC
J Pharmacol Exp Ther; 2010 Sep; 334(3):1023-30. PubMed ID: 20543097
[TBL] [Abstract][Full Text] [Related]
7. Liposomal doxorubicin attenuates cardiotoxicity via induction of interferon-related DNA damage resistance.
Gyöngyösi M; Lukovic D; Zlabinger K; Spannbauer A; Gugerell A; Pavo N; Traxler D; Pils D; Maurer G; Jakab A; Riesenhuber M; Pircher A; Winkler J; Bergler-Klein J
Cardiovasc Res; 2020 Apr; 116(5):970-982. PubMed ID: 31346605
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology of N-benzyladriamycin-14-valerate in the rat.
Sweatman TW; Seshadri R; Israel M
Cancer Chemother Pharmacol; 1999; 43(5):419-26. PubMed ID: 10100599
[TBL] [Abstract][Full Text] [Related]
9. Genotoxicity, nitric oxide level modulation and cardio-protective potential of Kalanchoe Integra Var. Crenata (Andr.) Cuf Leaves in murine models.
Asiedu-Gyekye IJ; Arhin E; Arthur SA; N'guessan BB; Amponsah SK
J Ethnopharmacol; 2022 Jan; 283():114640. PubMed ID: 34606947
[TBL] [Abstract][Full Text] [Related]
10. Cardioprotective Effect of Phase 3 Clinical Anticancer Agent, RRx-001, in Doxorubicin-Induced Acute Cardiotoxicity in Mice.
Oronsky B; Ao-Ieong ESY; Yalcin O; Carter CA; Cabrales P
Mol Pharm; 2019 Jul; 16(7):2929-2934. PubMed ID: 31038318
[TBL] [Abstract][Full Text] [Related]
11. Paroxetine mitigates cardiac remodelling by doxorubicin and increases survival.
Kosić M; Nešić Z; Glumac S; Vasić M; Pajović V; Savić B; Japundžić-Žigon N
Biomed Pharmacother; 2022 Jan; 145():112411. PubMed ID: 34781149
[TBL] [Abstract][Full Text] [Related]
12. The cardioprotective effects of an antiemetic drug, tropisetron, on cardiomyopathy related to doxorubicin.
Alimoradi H; Barzegar-Fallah A; Hassanzadeh G; Mohammadi-Rick S; Asadi F; Delfan B; Abbasi A; Dehpour AR
Cardiovasc Toxicol; 2012 Dec; 12(4):318-25. PubMed ID: 22744232
[TBL] [Abstract][Full Text] [Related]
13. Protective effect of paracetamol in doxorubicin-induced cardiotoxicity in ischemia/reperfused isolated rat heart.
Hesari M; Shackebaei D; Asadmobini A
Anatol J Cardiol; 2018 Feb; 19(2):94-99. PubMed ID: 29350208
[TBL] [Abstract][Full Text] [Related]
14. Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro.
Mukhopadhyay P; Rajesh M; Bátkai S; Kashiwaya Y; Haskó G; Liaudet L; Szabó C; Pacher P
Am J Physiol Heart Circ Physiol; 2009 May; 296(5):H1466-83. PubMed ID: 19286953
[TBL] [Abstract][Full Text] [Related]
15. Identification of protein targets underlying dietary nitrate-induced protection against doxorubicin cardiotoxicity.
Xi L; Zhu SG; Hobbs DC; Kukreja RC
J Cell Mol Med; 2011 Nov; 15(11):2512-24. PubMed ID: 21251210
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietin protects against doxorubicin-induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway.
Kim KH; Oudit GY; Backx PH
J Pharmacol Exp Ther; 2008 Jan; 324(1):160-9. PubMed ID: 17928571
[TBL] [Abstract][Full Text] [Related]
17. Sulforaphane protects the heart from doxorubicin-induced toxicity.
Singh P; Sharma R; McElhanon K; Allen CD; Megyesi JK; Beneš H; Singh SP
Free Radic Biol Med; 2015 Sep; 86():90-101. PubMed ID: 26025579
[TBL] [Abstract][Full Text] [Related]
18. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin.
Li K; Sung RY; Huang WZ; Yang M; Pong NH; Lee SM; Chan WY; Zhao H; To MY; Fok TF; Li CK; Wong YO; Ng PC
Circulation; 2006 May; 113(18):2211-20. PubMed ID: 16651473
[TBL] [Abstract][Full Text] [Related]
19. The Lack of Synergy between Carvedilol and the Preventive Effect of Dexrazoxane in the Model of Chronic Anthracycline-Induced Cardiomyopathy.
Szponar J; Ciechanski E; Ostrowska-Lesko M; Gorska A; Tchorz M; Dabrowska A; Dudka J; Murias M; Kowalczyk M; Korga-Plewko A; Mandziuk S
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373350
[TBL] [Abstract][Full Text] [Related]
20. Vitamin C mitigates oxidative/nitrosative stress and inflammation in doxorubicin-induced cardiomyopathy.
Akolkar G; da Silva Dias D; Ayyappan P; Bagchi AK; Jassal DS; Salemi VMC; Irigoyen MC; De Angelis K; Singal PK
Am J Physiol Heart Circ Physiol; 2017 Oct; 313(4):H795-H809. PubMed ID: 28710069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
